UK-based health monitoring startup Zedsen uses non-invasive biosensors to collect biophysical data from the bloodstream to provide customized patient health insights at scale. It claims to provide the world’s first technology to track biological tissues without the need for biopsy or fluid sample collection. The sensor technology involves using 3D sensor structures that are non-invasive and non-radiating while also being biologically inert. The sensor technology is constructed on a flexible substrate. This allows for the sensor to wrap and deform to a surface with no damage to the sensor.
Zedsen’s technology has 46 patents. Its patented technology creates a 3-Dimensional Multiplexing Electric Field Sensing technique (MEFS), identifying the electrical properties of any substance or material within the electrical field created by the sensor.
In April 2021, the company raised GBP 8.7 million (USD 12 million) in Series B funding, which was directed toward developing its product portfolio as well as investing in research and development and marketing.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.